Sangamo BioSciences Receives $6.4M Strategic Partnership Award from CIRM
May 24, 2013 at 07:02 AM EDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced that the California Institute for Regenerative Medicine (CIRM) has granted the Company a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its zinc finger nuclease (ZFN) gene-editing technology in hematopoietic stem
